55% / $36.6B / six IPOs. The number every health-AI deck cites is the same number that calls the top.
Bessemer's "State of Health AI 2026" published in late January and immediately became the canonical citation for every health-AI investor deck. Three numbers anchor the report. AI-enabled ventures captured 55% of all health-tech funding in 2025. Six health-tech IPOs added $36.6B in market cap. Non-AI digital health funding compressed substantially as capital reallocated to AI-narrative-bearing companies.
The numbers are real. Why do they call the top instead of confirming a sustainable trajectory?
The 55% / $36.6B / six-IPOs metrics track investor-class sentiment more than they track clinical evidence. The 2025 health-AI cohort is calibrated to a narrative that says AI compresses the deployment-vector friction that slowed the 2021 digital-health vintage. The reality is that the 2025 cohort faces the same reimbursement gaps, the same regulatory frameworks, the same physician-trust calibration curves that slowed the 2021 cohort. AI capability doesn't accelerate the four-gate deployment timeline (clinical-trial enrollment, regulatory review, payer reimbursement, physician-trust diffusion) at the rate the funding multiples are pricing.
What's the historical pattern? The digital-health-is-dead-to-AI-health-is-the-only-game shift from 2022 to 2025 is structurally similar to multiple prior healthcare-investment-narrative cycles. The wellness-startup wave (2018-2020). The COVID-telehealth surge (2020-2022). Each followed a similar arc: narrative crystallizes, capital floods in, exit multiples expand, then the deployment-vector friction surfaces and the cohort disappoints relative to the original capital-allocation thesis.
What gates are the 2025 cohort actually hitting? The same gates that slowed the 2021 vintage. Reimbursement coding for AI-enabled clinical workflows takes the same multi-year CMS-and-commercial-payer cycle as any new clinical category. FDA validation for AI-enabled diagnostics moves at agency-class speed independent of the AI capability. Physician-trust diffusion through the prescriber class follows historical adoption curves that AI doesn't accelerate. The 2025 cohort's pitch-deck assumptions about deployment velocity are operating-optimistic against the structural reality. Operators tracking the cohort should expect a 24-36 month gap between the funding event and the deployment-readiness milestone the deck promises.
When does the recalibration become operationally visible? In 2027-2028. The first wave of 2025 cohort companies will hit their Series-B / Series-C cycles in 2026-2027 with deployment metrics that lag the original projections. The second wave will hit IPO windows in 2028-2029 with revenue numbers calibrated to actual deployment velocity rather than to deck assumptions. The recalibration will surface in markdowns, pivot-class strategy adjustments, and acquisition-class consolidation as the larger players absorb the disappointing vintage. The pattern is structurally similar to the 2021-vintage digital-health recalibration that played out 2022-2024.
What strategy survives the recalibration? Position around durable deployment-vector capabilities, not around AI-narrative bearing. Companies whose value proposition is "AI capability X applied to healthcare workflow Y" are calibrated to the narrative cycle. Companies whose value proposition is "deployment-vector mechanism for category Z" — solving the labor bottleneck that gates wearable-RPM, solving the asymmetric-AI workflow that gates payer-provider integration, solving the middleware position that gates billing-code uptake — are calibrated to durable operator-class value. The recalibration will reward the latter and disappoint the former.
The same shape recurs across categories where AI capability is the entry framing. Healthcare-AI 2025-2026 is one example. Legal-AI 2024-2025 is in a similar arc with a 6-12 month earlier vintage timing. Financial-services-AI 2025-2026 is concurrent. Each category has its own recalibration timing, calibrated to category-specific deployment-vector friction. The categories with longest deployment-vector lags (healthcare, regulated finance, autonomous-mobility) produce the largest recalibration gaps.
What survives all of this is that Bessemer's 2026 numbers are the cleanest available articulation of where 2025 health-AI investor sentiment landed, the 55%/$36.6B/six-IPOs framing is operating-correct as a sentiment metric and operating-misleading as a deployment-velocity proxy, and the discipline is to position around deployment-vector durability rather than around the narrative-bearing that drove 2025's capital allocation. By 2027-2028 the recalibration will surface in vintage-cohort metrics. The cohort that positioned for deployment-vector durability is the cohort whose 2028 metrics support continued capital access; the cohort that positioned for narrative-bearing alone is the cohort whose 2028 metrics absorb the recalibration markdown.
55% / $36.6B / six IPOs. The number every health-AI deck cites is the same number that calls the top. The number is real. The narrative the number anchors is, in operating terms, less durable than the four-gate deployment-vector reality the narrative obscures. Operators reading both layers are calibrated to the structural environment. Operators reading only the headline are positioned for the recalibration that the historical pattern guarantees.
—TJ